Skip to main content
. 2021 Dec 7;10:e73430. doi: 10.7554/eLife.73430

Figure 1. Replication attempt of Sharma et al., 2010.

Growth characteristics of PC9 cells treated with various doses of erlotinib. (A) PC9 cells were plated at equal density and treated with dimethyl sulfoxide(DMSO) or the indicated dose of erlotinib (2 or 20 µM) for 9 days (fresh erlotinib was added every 3 days). Representative microscopic images of conditions on day 9. (B) Percent of drug-tolerant persisters (DTPs) as a percentage of DMSO control cells. PC9 cells were plated at various densities (cells/cm2) and treated with DMSO or the indicated concentrations of erlotinib. (C) Survival curve of PC9 cells treated with various doses of erlotinib for 72 hr. Percent survival is relative to DMSO-treated cells. The dashed line corresponds to 50% cell killing (absolute IC50 = 0.15 µM). Data plotted from one independent biological repeat. (D) Representative Western blots of lysates from PC9 cells treated with increasing concentrations of erlotinib (0.01, 0.1, 1, and 10 µM) or DMSO (0.01%). Membranes were probed with phospho-EGFR (pEGFR)-specific antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as loading control. Relative expression of pEGFR (to DMSO) for each concentration (0.01, 0.1, 1, and 10 µM erlotinib) is: 1.1, 1.2, 0.8, and 0.2, respectively. Each experiment was performed independently twice. Additional details can be found at https://osf.io/xbign/.

Figure 1.

Figure 1—figure supplement 1. Growth characteristics of PC9 cells treated with erlotinib hydrochloride (HCl).

Figure 1—figure supplement 1.

(A) PC9 cells were plated at equal density and treated with DMSO or the indicated dose of erlotinib HCl (2 or 20 µM) for 9 days (fresh erlotinib was added every 3 days). Representative microscopic images of conditions on day 9. (B) Percent of drug-tolerant persisters (DTPs) as a percentage of DMSO control cells. PC9 cells were plated at various densities (cells/cm2) and treated with DMSO or the indicated concentrations of erlotinib HCl. (C) Survival curve of PC9 cells treated with various doses of erlotinib for 72 hr. Percent survival is relative to DMSO-treated cells. The dashed line corresponds to 50% cell killing (absolute IC50 = 0.15 µM). Each experiment was performed once. Additional details can be found at https://osf.io/xbign/.